Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | HTR3A | P46098 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28452075 | 0.86 | SLC6A4 (0.45) | GAAARHTR1AHTR3AACHE | |
| SCHEMBL922844 | 0.85 | TSHR (0.41) | GAAARACHESLC6A4SMN1; SMN2 | |
| SCHEMBL446449 | 0.84 | AR (0.47) | GAAARHTR1AHTR3AACHE | |
| SCHEMBL4229054 | 0.81 | ALDH1A1 (0.42) | L3MBTL1SMN1; SMN2 | |
| SCHEMBL2266321 | 0.81 | PGR (0.39) | ARSMN1; SMN2 | |
| SCHEMBL2262676 | 0.80 | KDM4E (0.44) | GAASLC6A4L3MBTL1SMN1; SMN2HTR2A | |
| SCHEMBL2096609 | 0.80 | HTR2A (0.35) | ARSLC6A4L3MBTL1HTR2AKCNH2 | |
| SCHEMBL8484975 | 0.80 | NTRK1 (0.48) | GAAHTR1AHTR3ASMN1; SMN2 | |
| SCHEMBL921804 | 0.79 | SLC6A4 (0.42) | GAASLC6A4HTR2AKCNH2 | |
| SCHEMBL2750609 | 0.79 | GAA (0.38) | GAAARHTR1AHTR3AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465869-B1 | MODULATORS OF LXR | EXELIXIS PATENT CO LLC (US) | 2013-05-15 | — | — | EP | claimed |
| US-7998986-B2 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | claimed |
| EP-1465869-A4 | MODULATORS OF LXR | X CEPTOR THERAPEUTICS INC (US) | 2005-12-28 | — | — | EP | claimed |
| JP-2005536450-A | — | — | 2005-12-02 | — | — | JP | claimed |
| EP-1465869-A1 | MODULATORS OF LXR | X-Ceptor Therapeutics, Inc. (US) | 2004-10-13 | — | — | EP | claimed |
| US-20030181420-A1 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS, INC. | 2003-09-25 | — | — | US | claimed |
| WO-2003059884-A1 | MODULATORS OF LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-07-24 | — | — | WO | claimed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-1465869-B1 | MODULATORS OF LXR | EXELIXIS PATENT CO LLC (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8178540-B2 | Pyrimidylmethyl-sulfonamide compounds | BASF SE (DE) | 2012-05-15 | — | — | US | disclosed |
| US-20110201649-A1 | AGRICULTURAL COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-18 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1465869-A4 | MODULATORS OF LXR | X CEPTOR THERAPEUTICS INC (US) | 2005-12-28 | — | — | EP | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1465869-A1 | MODULATORS OF LXR | X-Ceptor Therapeutics, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20030181420-A1 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS, INC. | 2003-09-25 | — | — | US | disclosed |
| WO-2003059884-A1 | MODULATORS OF LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | GAA 4165/4885AR 254/4885HTR1A 4141/4885 |
| US-20030181420-A1 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | NR1H2, NR1H3, NCOA1 | GAA 3969/4885AR 213/4885HTR1A 607/4885 |
| US-20110201649-A1 | AGRICULTURAL COMPOSITION | H1-0, H1-3, H1-2 | GAA 2649/4885AR 1048/4885HTR1A 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.